期刊文献+

X染色体连锁的凋亡抑制蛋白、B淋巴细胞瘤-2及生存素在胸腺瘤中的表达及意义 被引量:6

Significance and expression of X chromosome linked inhibitor of apoptosis protein, B-cell lymphoma-2 and Survivin in thymoma
原文传递
导出
摘要 目的探讨X染色体连锁的凋亡抑制蛋白(XIAP)、B淋巴细胞瘤-2(bcl-2)及生存素(Survivin)在胸腺瘤中的表达及意义.方法收集2015年11月至2018年11月齐齐哈尔医学院第一附属医院收治45例胸腺瘤患者,采用免疫组织化学法检测19例胸腺增生组织,45例胸腺瘤及13例胸腺癌组织中XIAP、bcl-2、Survivin的表达,并分析三者与年龄、性别、组织学分型、临床分期、淋巴结转移及是否合并重症肌无力临床病理参数的关系.应用SPSS 17.0统计软件分析,计量资料采用x^2检验,相关分析采用Person相关分析.结果 XIAP在正常胸腺组织(2/19)、胸腺瘤组织(26/45)、胸腺癌组织(10/13)中的阳性表达依次升高,且差异有统计学意义(P<0.05).bcl-2在正常胸腺组织(2/19)、胸腺瘤组织(29/45)、胸腺癌组织(11/13)中的阳性表达依次升高(P<0.05),Survivin在正常胸腺组织(1/19)、胸腺瘤组织(23/45)、胸腺癌组织(11/13)中的阳性表达依次升高(P<0.05).胸腺瘤组织中XIAP、bcl-2及Survivin阳性表达率与临床分期、组织学分型有关(P<0.05),与年龄、性别、是否合并重症肌无力无关(P>0.05).经Pearson相关性分析,胸腺瘤中XIAP与bcl-2表达正相关(r=0.568,P<0.01),XIAP与Survivin表达正相关(r=0.671,P<0.01),bcl-2与Survivin表达正相关(r=0.529,P<0.01).结论 XIAP、bcl-2、Survivin在胸腺瘤组织中高表达,可作为判断胸腺瘤发生及恶性程度的预测指标. Objective To explore significance and expression of X chromosome linked inhibitor of apoptosis protein (XIAP), B-cell lymphoma-2 (bcl-2) and survivin in thymoma. MethodsThe expressions of XIAP, bcl-2 and Survivin in 19 cases of thymic hyperplasia, 45 cases of thymoma and 13 cases of thymic adenocarcinoma were detected by immunohistochemical method, and the relationship between the expression of XIAP, bcl-2 and Survivin and age, sex, histological type, clinical stage, ymph node metastasis and myasthenia gravis was analyzed. ResultsThe positive rate of XIAP in normal thymic tissue (2/19), thymoma (26/45) and thymic adenocarcinoma (10/13) increased in turn, and the difference was statistically significant (P<0.05). The positive rates of bcl-2 in normal thymic tissue (2/19), thymoma (29/45) and thymic adenocarcinoma (11/13) increased in turn (P<0.05). The positive rates of Survivin in normal thymic tissue (1/19), thymoma (23/45) and thymic adenocarcinoma (11/13) increased in turn (P<0.05). The positive rates of XIAP, bcl-2 and Survivin in thymoma tissues were correlated with histological type, clinical stage, ymph node metastasis, and was not correlated with age, sex and myasthenia gravis. The expressions of XIAP was correlated wih the expression of bcl-2 (r=0.568, P<0.01), the expression of XIAP was correlated with the expression of the expression of Survivin (r=0.671, P<0.01), the expression of bcl-2 was correlated with Survivin in thymoma tissues (r=0.529, P<0.01). ConclusionXIAP, bcl-2 and Survivin were highly expressed in thymoma tissues, which could be used as predictors of the occurrence and malignancy of thymoma.
作者 王天舒 信国玺 刘丛华 孙洪微 李志飞 Wang Tianshu;Xin Guoxi;Liu Conghua;Sun Hongwei;Li Zhifei(Department of Cardiothoracic Surgery,the First Affiliated Hospital of Qiqihar Medical College,Qiqihar161041,China;Department of Thoracic Surgery,Shanghai Lung Hospital,Shanghai 200433,China)
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2019年第7期1302-1305,共4页 Chinese Journal of Experimental Surgery
基金 黑龙江省卫生计划委科研课题(2017-274).
关键词 X染色体连锁的凋亡抑制蛋白 B淋巴细胞瘤-2 生存素 胸腺瘤 X chromosome linked inhibitor of apoptosis protein B-cell lymphoma-2 Survivin Thymoma
  • 相关文献

参考文献4

二级参考文献91

  • 1梁元姣,张慧明,郝群,徐艳,季爱华,胡娅莉.胰岛素样生长因子受体及雌激素受体在子宫内膜样腺癌中的表达及临床病理意义[J].医学研究生学报,2011,24(5):472-476. 被引量:6
  • 2Girard N, Shen R, Guo T, et al. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic car- cinomas and thymomas [ J ]. Clin Cancer Res, 2009,15 (22) :6790- 6799.
  • 3Lee GY, Yang WI, Jeung HC, et al. Genome-wide genetic aber- rations of thymoma using cDNA microarray based comparative ge- nomic hybridization[ J]. BMC Genomics, 2007, 8 ( 305 ) : 1471- 2164.
  • 4Inoue M, Starostik P, Zettl A, et al. Correlating genetic aberra- tions with World Health Organization-defined histology and stage across the spectrum of thymomas [ J]. Cancer Res, 2003,63 13 ) :3708-3715.
  • 5Zettl A, Strobel P, Wagner K, et al. Recurrent genetic aberra- tions in thymoma and thymic carcinoma [ J ]. Am J Pathol, 2000, 157 ( 1 ) :257-266.
  • 6Suzuki E, Sasaki H, Kawano O, et al. Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors [ J ]. Jpn J Clin Oncal, 2007,36 (6) : 351-356.
  • 7Meister M, Schirmacher P, Dienemann H, et al. Mutational sta- tus of the epidermal growth factor receptor (EGFR) gene in thy- momas and thymic carcinomas [ J ]. Cancer Lett ,2007,248 (2) : 186-191.
  • 8Yoh K, Nishiwaki Y, Ishii G, et al. Mutational status of EGFR and KIT in thymoma and thymic carcinoma [ J ]. Lung Cancer,2008,62 ( 3 ) : 316-320.
  • 9Aisner SC, Dahlberg S, FIarneed MR, et al. Epidermal growth factor receptor, C-kit, and Her2/neu immunostaining in ad- vanced or recurrent thymie epithelial neoplasms staged according to the 2004 World Health Organization in patients treated with oc- treotide and prednisone: an Eastern Cooperative Oncalogy Group Study[J]. J Thoracic Oncol, 2010, 5(6) : 885-892.
  • 10Ionescu DN, Sasatomi E, Cieply K, et al. Protein expression and gene amplification of epidermal growth factor receptor in thy- momas [ J ]. Cancer, 2005,103 (3) :630-636.

共引文献27

同被引文献33

引证文献6

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部